Psoriasis is an immune-mediated inflammatory skin disease, and its pathogenesis is related to inflammatory cell infiltration and inflammatory factors. GemPharmatech has independently developed two disease models: the IMQ-induced psoriasis mouse model and the B6-K14-hIL17A spontaneous psoriasis mouse model.
1. IMQ-induced psoriasis mouse model
Use C57BL/6JGpt and BALB/cJGpt female mice aged 6-8 weeks for the modeling. The modeling method involves continuous topical application of Imiquimod (IMQ) for 7 days.
Validation data
Efficacy results of Dexamethasone and Bifidobacterium in IMQ-induced psoriasis mouse model
A: Compared with G2 control group, the PASI score of G3 (Dexamethasone) and G4 (Bifidobacterium) groups was significantly decreased, and the silver disease phenotype was significantly alleviated.
B: Pathologic analysis of back skin.
2. B6-K14-hIL17A spontaneous psoriasis mouse model
H11-hKRT14-iCre (T004833) hybridized with Rosa26-CAG-LSL-hIL17A-IRES-EGFP-PolyA (T037029) to drive conditioned overexpression of IL-17A in keratinocytes, resulting in spontaneous psoriasis phenotype in mice.
Validation data
Phenotypic data of B6-K14-hIL17A spontaneous psoriasis mouse model
B6-K14-hIL17A psoriasis mouse model showed a significant psoriasis phenotype. Pathological analysis showed epidermal thickening, absence of granular layer, dermal elongation, hyperkeratosis and dyskeratosis, and multiple neutrophil abscesses in the stratum corneum.